SEATTLE, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA.
Adaptive’s management is scheduled to present on Tuesday, March 3, 2020, at 8:40am ET. Interested parties may access a webcast of the presentation on the “Investors” section of the company’s website at: http://investors.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com.
Investor Contact
Carrie Mendivil
investors@adaptivebiotech.com
Media Contact
Beth Keshishian
media@adaptivebiotech.com
Source: Adaptive Biotechnologies
